Reviva Pharmaceuticals Holdings Inc (RVPH)

Dec 19, 2024

Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance

Dec 19, 2024

Dec 18, 2024

Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World

Dec 18, 2024

Dec 17, 2024

Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch

Dec 17, 2024

Dec 17, 2024

CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline

Dec 17, 2024

Dec 16, 2024

Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan

Dec 16, 2024

Dec 16, 2024

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire

Dec 16, 2024

Dec 16, 2024

Reviva Announces Proposed Public Offering - GlobeNewswire

Dec 16, 2024

Dec 16, 2024

Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan

Dec 16, 2024

Dec 16, 2024

Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks

Dec 16, 2024

Dec 16, 2024

Reviva Announces Positive Preliminary Topline Data for the - GlobeNewswire

Dec 16, 2024

Dec 16, 2024

Reviva's Brilaroxazine Shows Promising Long-Term Results in Phase 3 Schizophrenia Trial - StockTitan

Dec 16, 2024

Dec 15, 2024

Reviva Pharmaceuticals Holdings, Inc. Holds Annual Meeting and Approves Increase in Authorized Shares - Defense World

Dec 15, 2024

Dec 13, 2024

Largest borrow rate increases among liquid names - TipRanks

Dec 13, 2024

Dec 13, 2024

Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH) - Defense World

Dec 13, 2024

Dec 11, 2024

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha

Dec 11, 2024

Nov 30, 2024

Analyzing Reviva Pharmaceuticals (NASDAQ:RVPH) and Akebia Therapeutics (NASDAQ:AKBA) - Defense World

Nov 30, 2024

Nov 19, 2024

RVPH: Year-End OLE Update - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Reviva Pharma: 108 Patients Complete 1-Year Schizophrenia Drug Trial as Losses Narrow | RVPH Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Reviva reports progress in schizophrenia treatment study By Investing.com - Investing.com Australia

Nov 14, 2024

Nov 12, 2024

Reviva reports progress in schizophrenia treatment study - Investing.com

Nov 12, 2024

Nov 12, 2024

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

Reviva's Brilaroxazine Hits Key Milestone: 108 Patients Complete 1-Year Schizophrenia Trial | RVPH Stock News - StockTitan

Nov 12, 2024

Nov 06, 2024

Reviva to Present Positive Speech Latency Data for - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit | RVPH Stock News - StockTitan

Nov 06, 2024

Oct 31, 2024

Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewswire

Oct 31, 2024

Oct 18, 2024

Reviva To Report Long-Term Safety Data For Brilaroxazine In Schizophrenia: Will The Stock Recover? - RTTNews

Oct 18, 2024

Oct 09, 2024

Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.

Oct 09, 2024

Oct 08, 2024

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 08, 2024

Oct 07, 2024

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst - Benzinga

Oct 07, 2024

Oct 02, 2024

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire

Oct 02, 2024

Sep 30, 2024

Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart

Sep 30, 2024

Sep 26, 2024

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times

Sep 26, 2024

Sep 23, 2024

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports

Sep 23, 2024

Sep 18, 2024

RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Sep 18, 2024

Sep 18, 2024

Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex

Sep 18, 2024

Sep 16, 2024

RVPH: RECOVER Biomarker KOL Event - Yahoo Finance

Sep 16, 2024

Sep 13, 2024

Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex

Sep 13, 2024

Sep 10, 2024

A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News

Sep 10, 2024

Sep 09, 2024

Reviva reports positive schizophrenia trial results - Investing.com India

Sep 09, 2024

Sep 09, 2024

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire

Sep 09, 2024

Sep 04, 2024

How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News

Sep 04, 2024

Sep 04, 2024

Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Sep 04, 2024

Sep 04, 2024

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 04, 2024